Zoetis Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 39/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 164.86.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zoetis Inc's Score
Industry at a Glance
Industry Ranking
39 / 159
Overall Ranking
111 / 4592
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
20
analysts
Buy
Current Rating
164.863
Target Price
+39.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Zoetis Inc Highlights
StrengthsRisks
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.26B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 32.66%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 32.66%.
Undervalued
The company’s latest PE is 19.98, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 435.62M shares, decreasing 0.32% quarter-over-quarter.
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Ticker SymbolZTS
CompanyZoetis Inc
CEOPeck (Kristin C)
Websitehttps://www.zoetis.com/
FAQs
What is the current price of Zoetis Inc (ZTS)?
The current price of Zoetis Inc (ZTS) is 118.660.
What is the symbol of Zoetis Inc?
The ticker symbol of Zoetis Inc is ZTS.
What is the 52-week high of Zoetis Inc?
The 52-week high of Zoetis Inc is 181.850.
What is the 52-week low of Zoetis Inc?
The 52-week low of Zoetis Inc is 115.250.
What is the market capitalization of Zoetis Inc?
The market capitalization of Zoetis Inc is 52.38B.
What is the net income of Zoetis Inc?
The net income of Zoetis Inc is 2.49B.
Is Zoetis Inc (ZTS) currently rated as Buy, Hold, or Sell?
According to analysts, Zoetis Inc (ZTS) has an overall rating of Buy, with a price target of 164.863.
What is the Earnings Per Share (EPS TTM) of Zoetis Inc (ZTS)?
The Earnings Per Share (EPS TTM) of Zoetis Inc (ZTS) is 5.940.